OOIR: Observatory of International Research

Papers

(The H4-Index of International Journal of Radiation Oncology Biology Physics is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
The R's of Radiation Therapy: Do We Need More or Do We Move On?	209
If Medicine were my Spouse	163
In Regard to Langé et al	155
Spatially Fractionated Radiation Therapy (SFRT) Based on Multimodal Imaging: A Promising Salvage Treatment Strategy for Metastatic and Refractory Cancer Patients	131
The Positioning Accuracy of Individualized Open-Face Mask in Patients with Intracranial Tumors Receiving Radiotherapy - A Randomized Controlled Study	131
“Big Jolts Like an Electric Shock:” Patient Perspectives on the Expectations, Experiences and Quality-of-Life Impact of Androgen Deprivation Therapy (ADT) for Prostate Cancer	113
Can Surface-Guided Radiation Therapy (SGRT) be Used to Monitor Intrafraction Motion of Patients Receiving Accelerated Partial Breast Irradiation (APBI)?	105
The Association of Genetic Polymorphisms in the TNF-α Gene and Mucositis in Head and Neck Cancer Patients Treated with Combined Radiotherapy and Chemotherapy	101
Locoregional Recurrence and Survival Outcome of HER2-Low Breast Cancer Patients after Upfront Surgery and Adjuvant Radiotherapy	88
Applying GD-EOB-DTPA Enhanced MR to Unveil the Radiobiological Effect of Proton and Photon Therapy Based on the Longitudinal Evolution of the Focal Liver Reaction	85
Multi-Modality Machine Learning Prediction Model of Hematologic Toxicity in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer	85
Development of a Consensus Checklist for Systematic Radiation Treatment Plan Review	83
Withdrawn	77
Partial Kidney Radiation Modeling for the Effect of Kidney Dysfunction in Pediatric Cancer	76
Predictive Analysis of DQA (Delivery Quality Assurance) Failures in Tomotherapy Plans: Utilizing Plan Parameters and Dosiomics	70
Adoption of Hypofractionated and Ultrahypofractionated Adjuvant Radiation Therapy for Breast Cancer Treatment among Providers at a Large Academic Medical Center	70
Clinical Outcomes of Patients with Early-Stage Breast Cancer Treated with Five-Fraction Partial Breast Irradiation vs. Intraoperative Radiation Therapy	68
Personalized Minimal Residual Disease Profiling Predicts Prognosis in Esophageal Carcinoma Undergoing Definitive Radiotherapy	67
A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes	66
Initial Clinical Experience of Cherenkov Imaging in Sub-Total Total Skin Electron Therapy Identifies Opportunities to Improve Daily Set-Up QA	64
Evaluating the Efficacy of Novel MET-Targeting Camelid Derived Antibody as an Imaging Agent in Head and Neck Cancers	64
Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320)	63
A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy	62
Phase I/II Prospective Dose Escalation Trial with Proton-Based Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base and Cervical Spine: Long-Term Results from Proton Radiation Oncolog	58
Prostate CAncer Integrated Risk Evaluation (P-CARE): A Model to Stratify Risk of Any, Metastatic, and Fatal Prostate	57

Spatiotemporal Fractionation Schemes and Additional OAR Sparing for Single-Beam-per-Fraction FLASH-RT Using Transmission Proton Beam	57
Development of Volumetric Quantitative Evaluation Software for Assessing Respiratory-Induced Target Motion	54
Feasibility of an Online MR-Guided Scan-Plan-Treat Workflow for Emergency Palliation	52
Deep Dive into the Performance of the 5D Breathing Motion Model	52
Dosimetric Comparison between Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy in Both Semi-Lateral Decubitus and Supine Positions for Left Breast Cancer Radiation T	51
Adaptive Radiation Fractionation in Head and Neck Cancer through Modeling Tumor Volume Dynamics	51
Assessing Dose Uncertainties in Cardiac SBRT due to Cardiorespiratory Motion: Photon vs. Proton Therapy Comparison	51
Lost in Lunglation: Unraveling the Mystery of Idiopathic Pulmonary Syndrome Post-Total Body Irradiation for Bone Marrow Transplant	49
Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis	48
Role of Retreatment with Stereotactic Ablative Body Radiotherapy (SABR) in Oligorecurrent Mesothelioma: A Retrospective Monocentric Study	48
Impact of Resident-Lead Didactics on Referring Trainee Radiotherapy Knowledge and Consultation Comfort	48
Multi-Omics Sequencing Unveils Tumor Microenvironment Remodeling Induced by Combined Radiotherapy and Immunotherapy in Microsatellite-Stable Locally Advanced Rectal Cancer	47
Microboost and Dosimetric Variability in Localized Prostate Cancer: Analysis of a Prospective Statewide Quality Collaborative	46
Transforming into a Trauma-Informed Care Radiation Oncology Department: Training Program Design, Execution and Evaluation of our Program's Impact	46
A Single Arm Phase II Study of Neoadjuvant Chemoradiotherapy and AK104 in pMMR/MSS Locally Advanced Rectal Cancer with Positive PD-L1 Expression	46
Geographical Comparison of Medicare & Medicaid Services (CMS) Standard Charges for Complex Proton Therapy	46
Timing of Once-Daily Thoracic Radiotherapy and Clinical Outcomes in Patients with Limited-Stage Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy	45
A Meta-Analysis of Daily vs. Nonconsecutive Fractionation Schedules for Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer	45
Association of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy	45
Predictors of Local Failure in the Durable Palliation of Recurrent Breast Cancer Following Concurrent Hyperthermia and High Dose Radiation	44
Stereotactic Body Radiation Following Prior Radiotherapy for Pancreatic Cancer: A Single Institution Experience	44
Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)	44